Last reviewed 2026-05-14 · How we verify

Diclofenac diethylamine 2.32% gel

Diclofenac diethylamine 2.32% gel is a Nonsteroidal anti-inflammatory drug (NSAID) Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Topical treatment of localized pain and inflammation associated with musculoskeletal conditions (e.g., sprains, strains, osteoarthritis).

Diclofenac diethylamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of application.

Diclofenac diethylamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of application. Used for Topical treatment of localized pain and inflammation associated with musculoskeletal conditions (e.g., sprains, strains, osteoarthritis).

At a glance

Mechanism of action

Diclofenac works by blocking COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. The diethylamine salt formulation enhances skin penetration when applied topically as a gel, allowing the active drug to reach affected tissues. This localized delivery minimizes systemic exposure compared to oral NSAIDs.

Approved indications

• Topical treatment of localized pain and inflammation associated with musculoskeletal conditions (e.g., sprains, strains, osteoarthritis)

Common side effects

• Local skin irritation or erythema
• Contact dermatitis
• Photosensitivity

Key clinical trials

• A Clinical Trial to Compare Safety and Effectiveness for Relieving Tenderness of 10% Naproxen Gel vs. a 2.32% Diclofenac Diethylamine Gel in the Treatment of Strains and Bruises of the Legs. (PHASE2)
• Voltaren Emulgel 2% Acute Ankle Sprain Non Inferiority Study (PHASE3)
• A Study to Characterize Diclofenac's Plasma and Knee Exposure After Application of Diclofenac Gel to the Knee of Subjects With Osteoarthritis That Have a Scheduled Arthroplasty (PHASE1)
• Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA) (PHASE3)
• Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Twice or Three Times Daily in Patients With Acute Ankle Sprain (PHASE3)
• Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel in Patients With Acute Ankle Sprain (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Diclofenac diethylamine 2.32% gel CI brief — competitive landscape report
• Diclofenac diethylamine 2.32% gel updates RSS · CI watch RSS
• GlaxoSmithKline portfolio CI

Frequently asked questions about Diclofenac diethylamine 2.32% gel

Related

• Drug class: All Nonsteroidal anti-inflammatory drug (NSAID) drugs
• Target: All drugs targeting Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
• Manufacturer: GlaxoSmithKline — full pipeline
• Therapeutic area: All drugs in Pain Management / Rheumatology
• Indication: Drugs for Topical treatment of localized pain and inflammation associated with musculoskeletal conditions (e.g., sprains, strains, osteoarthritis)
• Compare: Diclofenac diethylamine 2.32% gel vs similar drugs
• Pricing: Diclofenac diethylamine 2.32% gel cost, discount & access